A Novel Anti-Cancer/Anti-Proliferation and Anti-Migration Compound—An Inhibitor to Dual Specificity Phosphatase Slingshot-2
Tech ID: 21653 / UC Case 2010-247-0
BackgroundCell growth and movement are controlled in part through the activation of a dual specificity phosphatase (DSP) called Slingshot-2 (SSH-2). SSH-2 is known to contribute to the progression of cancer and Alzheimer’s disease. Therefore, finding a specific inhibitor for SSH-2 may have a profound impact in clinical treatments of these diseases.
Technology DescriptionScientists at UC San Diego have found a family of small molecule inhibitors that specifically binds to SSH-2. These compounds represent the first inhibitors of a phosphatase that regulates the F-actin depolymerization.
The inventors used a molecular docking simulation software (DOCK 6.0) to virtually screen open-source chemical databases and determined the binding affinities to 18 of DSPs with known three-dimensional structures as determined by x-ray crystallography, including SSH-2, VHR (DUSP3), VHY (DUSP15), VHZ (DUSP23), VH1 (DUSP12), VH3 (DUSP5), PTEN (phosphatase and tensin homolog), KAP (Cdk2 associated protein phosphatase), MKP3 (rVH6, Pyst1), MKP4, MKP5, MTMR2, DUSP18, PRL3, CDC14b, Pac-1, Jsp-1, and TMPD. Five compounds with similar chemical structures have the highest affinity for SSH-2, but lowest affinity for the other DSPs, among the best 100 SSH-2 binding compounds.
Figure 1. Diagram illustrating the role of phosphorylation and SSH-2 in actin filament assembly.
AdvantagesHighly specific SSH-2 inhibitor that regulates F-actin depolymerization.
ApplicationsNew therapeutics, targeting actin filament dynamics and signaling pathways, for the treatment of cancer, Alzheimer’s, and other diseases.
State Of DevelopmentVirtual screening yielded a compound with high binding affinity to SSH-2 and very low binding affinity to other DSPs.
- Mui MK , Levesque MJ, Chien S, and Haga JH. In-Silico Identification of High Potential SSH-2 Specific Inhibitors. The FASAB J. (1_MeetingAbstracts) Apr 2010; 24 No. 1060.3.
|Patent Cooperation Treaty||Published Application||WO 2012/129057||09/27/2012||2010-247|
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- FirmocidinTM, A New Small-Molecule Antibiotic to Treat MRSA, Staph, and Streptococcus Infections
- New Chemical Entities for Treatment of Brain Cancer
- Marine Natural Product Yields Cancer Therapeutic (NCE)
- Selective Phospholipase A2 Inhibitors of Neurological Diseases
- Phosphonates with Reduced Toxicity for Treatment of Viral Diseases